Mannitol IS Still Widely Used—The Premise of This Question is Incorrect
Mannitol remains a recommended first-line osmotic agent for managing elevated intracranial pressure and is NOT being phased out of clinical practice. Current guidelines from 2018 explicitly recommend mannitol 20% at equiosmolar doses (250 mOsm) for treating intracranial hypertension, with Grade 1+ evidence and strong agreement 1. The FDA continues to approve mannitol for reduction of intracranial pressure and brain mass 2.
Why the Misconception Exists
The perception that mannitol is being replaced stems from the emergence of hypertonic saline (HTS) as an alternative option, not a replacement. Here's the nuanced reality:
Both Agents Remain Equally Recommended
At equiosmolar doses (approximately 250 mOsm), mannitol and hypertonic saline demonstrate comparable efficacy for treating intracranial hypertension 1. The 2018 guidelines explicitly state both are acceptable first-line options, administered over 15-20 minutes for threatened intracranial hypertension or signs of brain herniation 1.
The Evidence Landscape
While some meta-analyses suggest HTS may be marginally more effective at reducing ICP (mean difference of 2.0 mmHg favoring HTS) 3, no clear benefit in long-term neurological outcomes has been demonstrated for either agent 4. A 2025 pediatric meta-analysis found no significant differences in mortality (RR 0.91,95% CI 0.54-1.52), ICP changes, or cerebral perfusion pressure between the two agents 5.
Clinical Decision-Making Algorithm
Choose mannitol when:
- Patient has hypernatremia or hyperchloremia (mannitol avoids these complications)
- Adequate IV access and ability to monitor fluid status exists
- Patient can tolerate osmotic diuresis with volume replacement
Choose hypertonic saline when:
- Patient is hypovolemic or hypotensive (HTS provides volume expansion)
- Concern exists about renal function with repeated dosing
- Patient has pre-existing electrolyte abnormalities that mannitol might worsen
Critical Caveats and Pitfalls
Mannitol's Specific Limitations
- Osmotic diuresis requires volume compensation—failure to replace urinary losses leads to hypovolemia 1
- Rebound ICP elevation can occur, particularly in ischemic stroke (days 5-7 post-event) 6
- Risk of acute kidney injury with repeated dosing, especially with pre-existing renal disease or concomitant nephrotoxic drugs 2
- May worsen outcomes in acute ischemic stroke when intracranial pressure is not the primary issue—mannitol reduced regional plasma volume and increased infarct size in experimental models 7
When NOT to Use Mannitol
The FDA label explicitly contraindicates mannitol in 2:
- Well-established anuria from severe renal disease
- Severe pulmonary congestion or frank pulmonary edema
- Active intracranial bleeding (except during craniotomy)
- Severe dehydration
- Progressive heart failure after mannitol initiation
Monitoring Requirements
Both agents require vigilant monitoring of fluid balance, serum sodium, chloride, and osmolarity 1. Discontinue if renal, cardiac, or pulmonary status worsens 2.
The Bottom Line
Mannitol has not been abandoned—it remains guideline-recommended and FDA-approved for managing elevated ICP. The choice between mannitol and hypertonic saline should be based on individual patient factors (volume status, electrolytes, renal function) rather than a blanket preference for one over the other. The 2022 Lancet Neurology review confirms both agents continue to be studied and used in contemporary TBI management 8.
The key is understanding that mannitol's side effect profile (osmotic diuresis, potential renal injury) differs from HTS (hypernatremia, hyperchloremia), allowing clinicians to select the most appropriate agent based on the clinical context rather than abandoning either option.